Artemis Medicare Services Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹274Cr
- +16.6% YoY
- +2.6% QoQ
- Net profit
- ₹30Cr
- +30.4% YoY
- +30.4% QoQ
- Margin
- 18%
- +3 pp YoY
- +2 pp QoQ
Guidance rank: #17 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Artemis Medicare anticipates a 15% to 17% annual revenue growth from flagship hospitals over the next 3-4 years. Revenue growth of 15% to 17% year-on-year expected from flagship hospitals over next 3-4 years (Rudra Acharjee, Pg 16).
From Artemis Medicare Services Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Artemis Medicare anticipates a 15% to 17% annual revenue growth from flagship hospitals over the next 3-4 years.
- Expansion plans include increasing operational beds from 544 currently and adding 200 beds at Raipur, targeting 2,000+ beds by 2029.
- International patient revenue is expected to remain around 30-31%, with ongoing geographic diversification.
- The Gurgaon facility aims to increase occupancy from ~64.6% to 70-75% by Q2 FY27, supporting revenue growth.
- A 15% overall increase in top line is budgeted for both domestic and international patients, with price hikes of about 15%.
2 more points from Artemis Medicare Services Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Artemis Medicare Services Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Gurgaon: Potential addition of 100 beds; plan to open 50 beds once 70% occupancy is achieved, followed by another 50 beds; capital allocation focusing on extension and maturity of existing towers.
- New South Delhi & Raipur facilities:
- Raipur: 650-bed facility planned in two phases (450 beds and 200 beds); capex around INR 500 crores (INR 350 crores for first 450 beds, INR 150-160 crores for next 200 beds); interiors and equipment included; Raipur operational beds to reach 300 within two quarters post-launch.
- South Delhi: 650 beds planned; capex to start post-FY27 with major expenses from FY28 onwards; includes interiors and equipment, land/building owned by trust.
- Additional capex of INR 100 crores planned in FY27 for Gurgaon replacement and fitting for Raipur.
2 more points from Artemis Medicare Services Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Artemis Medicare Services Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Artemis Medicare Services Ltd said on order book & pipeline — free account, 30 seconds.
Artemis Medicare Services Ltd — Quarterly revenue & net profit
Artemis Medicare Services Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 274 | 235 | +16.6% | 267 | +2.6% |
| Operating profit (EBITDA) | 50 | 36 | +38.9% | 44 | +13.6% |
| Operating margin | 18% | 15% | +3 pp | 16% | +2 pp |
| Profit before tax | 39 | 29 | +34.5% | 30 | +30% |
| Net profit (PAT) | 30 | 23 | +30.4% | 23 | +30.4% |
| EPS (₹) | 1.87 | 1.69 | +10.7% | 1.42 | +31.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹306 Cr, net profit ₹31 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Artemis Medicare's management said in earlier quarters
Others in Healthcare Services this season
- Suven Life Sciences (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnostic (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…
- KMC Speciality (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Artemis Medicare Services Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Artemis Medicare Services Ltd Q4 FY26 results?
Artemis Medicare anticipates a 15% to 17% annual revenue growth from flagship hospitals over the next 3-4 years. Revenue growth of 15% to 17% year-on-year expected from flagship hospitals over next 3-4 years (Rudra Acharjee, Pg 16).
What is Artemis Medicare Services Ltd share price analysis?
Artemis Medicare Services Ltd currently shows a neutral. The stock trades at a P/E of 44.2 with a market cap of ₹5,100 Cr. Investors should review the full earnings analysis for detailed insights.
Is Artemis Medicare Services Ltd planning capital expenditure?
Gurgaon: Potential addition of 100 beds; plan to open 50 beds once 70% occupancy is achieved, followed by another 50 beds; capital allocation focusing on extension and maturity of existing towers.
Keep Artemis Medicare Services Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
